![]()
The Business Research Company’s Verluma Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035
LONDON, GREATER LONDON , UNITED KINGDOM, November 19, 2026 /EINPresswire.com/ — The Verluma market is gaining considerable attention as advancements in nuclear imaging and oncology diagnostics progress. With rising cancer cases worldwide and growing clinical acceptance of innovative imaging agents, the market is set to experience dynamic growth. Below, we explore the current market size, key drivers behind its expansion, and regional growth forecasts.
Understanding the Verluma Market Size and Its Growth Factors
The Verluma market has seen significant growth in the past, largely driven by breakthroughs in nuclear imaging technologies. Other factors include a higher prevalence of colorectal and solid tumors, improved access to radiopharmaceuticals, the expansion of oncology diagnostic infrastructure, and broader clinical acceptance of targeted imaging agents. Looking ahead, the market is expected to continue its upward trajectory, supported by the increasing demand for personalized cancer diagnostics, rising investments in nuclear medicine facilities, and the growing role of companion diagnostics in oncology. Additional drivers include the expanded use of molecular imaging for cancer staging and ongoing innovations in radiolabeled antibody fragments. Trends forecasted to shape this market involve wider adoption of targeted radiolabeled diagnostics, increased utilization of CEA-targeted imaging agents, the growing need for early cancer detection tools, broader applications of nuclear medicine imaging, and deeper integration of precision oncology diagnostics.
Download a free sample of the verluma market report:
https://thebusinessresearchcompany.com/sample_request?id=89941206&type=smp&name=Verluma%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR
What Verluma Is and How It Works in Cancer Detection
Verluma is a radiolabeled monoclonal antibody fragment specifically designed for nuclear medicine applications. It targets carcinoembryonic antigen (CEA), a protein commonly overexpressed in certain cancers. By binding to tumor cells that express CEA, Verluma aids in detecting and staging cancers such as colorectal cancer. This targeting enables visualization using imaging techniques like SPECT, providing clinicians with detailed information to guide diagnosis and treatment.
Increasing Cancer Incidence as a Key Driver for Verluma Market Growth
One of the primary factors propelling the Verluma market is the rising number of cancer cases worldwide. Cancer involves uncontrolled cell growth that can invade nearby tissues and spread through blood and lymph systems. Factors such as aging populations, lifestyle changes, and the globalization of risk elements contribute to this rise. Verluma serves as a therapeutic device employing advanced technologies, including electromagnetic fields and non-invasive methods, to potentially disrupt cancer cell growth. Additionally, it supports healing and enhances the body’s response to other treatments. For instance, the American Cancer Society reported approximately 313,510 new breast cancer cases in 2024 in the US, up from 300,590 in 2023. This increasing cancer burden is a strong catalyst for market growth.
View the full verluma market report:
https://thebusinessresearchcompany.com/report/verluma-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR
The Role of Growing Demand for Diagnostic Imaging Procedures in Verluma Market Expansion
Another significant driver of Verluma’s market growth is the rising need for diagnostic imaging procedures. These procedures create visual representations of the body’s interior to support clinical assessments and medical interventions. Demand has surged due to the increasing prevalence of chronic diseases, greater emphasis on early detection and preventive healthcare, and improved healthcare access globally. Verluma enhances these imaging procedures by improving image quality through advanced algorithms, which leads to more accurate detection and better patient outcomes. To illustrate, the National Health Service in England reported 45.0 million imaging tests conducted by March 2023, a 2.2% rise from 44.0 million tests in 2022, highlighting the growing utilization of such technologies.
How Rising Healthcare Expenditure Is Supporting Verluma Market Development
The continuous increase in healthcare spending is another important factor driving Verluma’s market growth. Healthcare expenditure includes all financial resources allocated for medical treatments, hospital services, pharmaceuticals, infrastructure, and preventive care. This rise is fueled by aging demographics, higher chronic disease prevalence, technological advancements, and stronger demand for healthcare services. Increased healthcare budgets encourage providers to invest in cutting-edge technologies like Verluma, which improve patient outcomes and operational efficiency. For example, the UK’s Office for National Statistics projected healthcare spending to reach £317 billion in 2024, marking a 6.5% nominal increase and a 2.4% rise in real terms from 2023. Long-term care expenditure also grew by 3.1% in real terms in 2023, mainly due to greater government spending. Such financial trends bolster the market potential for advanced diagnostic tools like Verluma.
North America Leading as the Fastest Growing Region in the Verluma Market
In terms of regional outlook, North America held the largest share of the Verluma market in 2025. Other key regions covered in the market analysis include Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa. However, North America is expected to remain at the forefront of market expansion due to its advanced healthcare infrastructure, strong investment in nuclear medicine technologies, and high cancer incidence rates driving demand for precision diagnostics.
Key enhancements in our 2026 market reports include:
• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables
Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info
The Business Research Company – www.thebusinessresearchcompany.com
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company
Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
![]()
Media gallery
